Litigation Details for Eli Lilly and Company v. Apotex, Inc. (E.D. Va. 2016)

« Back to Dashboard

Eli Lilly and Company v. Apotex, Inc. (E.D. Va. 2016)

Docket		Date Filed	2016-11-30
Court	District Court, E.D. Virginia	Date Terminated	2017-03-13
Cause	35:271 Patent Infringement	Assigned To	Anthony John Trenga
Jury Demand	None	Referred To	Michael S. Nachmanoff
Patents	6,943,166
Link to Docket	External link to docket

Details for Eli Lilly and Company v. Apotex, Inc. (E.D. Va. 2016)

Date Filed	Document No.	Description	Snippet	Link To Document
2016-11-30				External link to document
2016-11-29	1		e)(2) for infringement of U.S. Patent No. 6,943,166 (“the ’166 patent”). … 1. This is an action for patent infringement arising under the patent laws of the United States, … PATENT-IN-SUIT 30. On September 13, 2005, the U.S. Patent and Trademark Office…copy of the ’166 patent is attached hereto as Exhibit A. The claims of the ’166 patent are valid and enforceable…and 20 mg dosage strengths. The ’166 patent is one of the patents listed in the FDA publication entitled	External link to document
2016-11-29	11		is enjoined from infringing U.S. Patent No. 6,943,166 ("the '166 patent"), on its own part or through any…2016 13 March 2017 1:17-cv-00015 830 Patent None District Court, E.D. Virginia	External link to document

Eli Lilly v. Apotex, Inc. 1:17-cv-00015: Cialis Patent Litigation Summary and Analysis

Last updated: August 31, 2026

Eli Lilly and Company sued Apotex, Inc. in the U.S. District Court for the District of Delaware after Apotex filed an Abbreviated New Drug Application seeking approval to market generic tadalafil tablets. The case involved Lilly’s patent covering tadalafil for benign prostatic hyperplasia, or BPH, an indication associated with Cialis. The matter was resolved without a reported trial judgment on validity or infringement, and the public docket does not disclose the commercial terms of the parties’ resolution. [1]

What drug and patent were at issue in Eli Lilly v. Apotex?

The litigation concerned tadalafil, the active pharmaceutical ingredient in Cialis. Lilly marketed Cialis for erectile dysfunction and BPH. Apotex’s ANDA sought approval for generic tadalafil tablets in strengths corresponding to Cialis products.

The principal patent identified in the litigation was U.S. Patent No. 8,791,124, titled “Tadalafil for the Treatment of Benign Prostatic Hyperplasia.” The patent issued July 29, 2014, and claimed methods involving tadalafil for treating BPH. [1][2]

Item	Detail
Plaintiff	Eli Lilly and Company
Defendant	Apotex, Inc.
Court	U.S. District Court for the District of Delaware
Civil action	No. 1:17-cv-00015
Judge	Richard G. Andrews
Product	Generic tadalafil tablets
Reference drug	Cialis
Active ingredient	Tadalafil
Primary patent	U.S. Patent No. 8,791,124
Filing date	January 9, 2017
Litigation type	Hatch-Waxman ANDA patent litigation
Regulatory mechanism	Paragraph IV certification
Public outcome	Resolved without a reported merits judgment

What was the legal basis for Lilly’s lawsuit?

Lilly filed the action under the Hatch-Waxman Act after receiving notice that Apotex had submitted a Paragraph IV certification to the FDA.

A Paragraph IV certification asserts that a listed patent is invalid, unenforceable, or will not be infringed by the proposed generic product. Filing a Paragraph IV notice gives the branded manufacturer an opportunity to sue before FDA approval. A timely infringement action generally triggers a 30-month stay of FDA approval, subject to statutory exceptions. [3]

Lilly alleged that Apotex’s proposed tadalafil product would infringe the ’124 patent. The asserted theory focused on the proposed product’s labeling and use for BPH. Apotex’s expected defenses were invalidity, noninfringement, and the statutory defense that the ANDA submission itself did not constitute actionable infringement for the claimed uses.

The case therefore presented the standard Hatch-Waxman dispute:

1. Whether Apotex’s proposed ANDA product and labeling would induce infringement of the ’124 patent.
2. Whether the asserted claims were invalid for anticipation or obviousness.
3. Whether the FDA-approved label could be structured to avoid the patented BPH use.
4. Whether the patent would remain enforceable through the expected commercial launch period.

When did U.S. Patent No. 8,791,124 expire?

The ’124 patent had an estimated expiration date in 2026, before any applicable patent-term adjustment or pediatric exclusivity. FDA Orange Book records should be used for the operative listed expiration and regulatory status. [2]

Patent	Subject matter	Approximate patent expiration	Commercial relevance
U.S. 8,791,124	Tadalafil treatment for BPH	2026	Delayed or constrained generic BPH labeling
Earlier Cialis patents	Tadalafil compound, formulations, and related uses	Primarily expired or nearing expiration by 2017-2020	Reduced protection for the core erectile-dysfunction product

The ’124 patent was commercially significant because the basic tadalafil compound and earlier Cialis patents were approaching expiration. The patent extended protection around a specific therapeutic indication rather than preserving a broad monopoly over tadalafil in every use.

A generic applicant could seek approval for a product that excluded the patented BPH indication through a section viii “skinny label,” provided the remaining label did not encourage infringement. The practical strength of the patent therefore depended on the scope of the proposed labeling, physician prescribing behavior, and the evidence available to establish induced infringement.

What was the Orange Book status of Cialis and tadalafil?

Cialis was approved by the FDA as a tadalafil product. The Orange Book listed patents associated with Cialis, including patents covering tadalafil-related methods and product protection. [2]

The regulatory position had several components:

• Core erectile-dysfunction protection was subject to earlier patent expirations.
• The BPH indication was supported by later method-of-use patent protection.
• FDA approval of an ANDA depended on the applicant’s certifications to each listed patent.
• A Paragraph IV notice exposed the applicant to patent litigation.
• A section viii carve-out could permit approval for nonpatented indications if the proposed label excluded the patented use.

The Orange Book did not determine infringement. It identified patents that could create regulatory delay or litigation risk. The district court, not the FDA, would decide patent validity and infringement.

How strong was Lilly’s patent estate against Apotex?

Lilly’s patent position was mixed rather than uniformly strong.

Strengths of the ’124 patent

The ’124 patent had several commercial advantages:

• It covered an approved Cialis indication, BPH.
• It remained in force well after the expiration of earlier tadalafil protection.
• It could delay an unrestricted generic launch if the ANDA label included BPH treatment.
• A finding of induced infringement could arise from the product label, marketing materials, or other evidence showing encouragement of the patented use.

Limitations of the patent

The patent also had structural weaknesses:

• It was a method-of-use patent, not a broad composition-of-matter patent.
• A generic manufacturer could seek a skinny label.
• Infringement would depend heavily on the proposed labeling and instructions.
• The patent did not prevent all tadalafil competition for erectile dysfunction.
• A generic could argue that the claimed treatment method was obvious in view of tadalafil’s known pharmacology and clinical data.

The case did not produce a publicly reported claim-construction decision, summary-judgment ruling, or trial verdict establishing how the court would have assessed those issues. As a result, the docket does not establish a judicial finding that the ’124 patent was either exceptionally strong or invalid.

What litigation events occurred in the case?

The public record reflects a conventional ANDA case filed in early 2017. Lilly initiated the action after Apotex’s Paragraph IV notice. Apotex was positioned to challenge the patent and defend against Lilly’s infringement claims.

Date or period	Event
January 9, 2017	Lilly filed the complaint against Apotex in Delaware
2017	Apotex defended against the asserted tadalafil patent claims
2017-2018	The parties litigated the ANDA patent dispute and negotiated resolution
Resolution period	The case ended without a reported merits trial judgment
Post-resolution	The public docket did not disclose the commercial settlement terms

The absence of a published merits opinion means the case is more important as a market-access event than as binding patent precedent. It did not establish a new rule governing tadalafil method-of-use patents.

Did Lilly and Apotex enter a settlement agreement?

The public record indicates that the dispute was resolved rather than adjudicated through a publicly reported final judgment. The settlement terms were not publicly disclosed in the case materials generally available for review. [1]

Important terms that are not established by the public docket include:

• The date on which Apotex could launch.
• Whether Apotex received a license to the ’124 patent.
• Whether launch was limited to erectile dysfunction or included BPH.
• Whether Apotex agreed to a delayed launch date.
• Whether the agreement included supply, authorized-generic, or other commercial provisions.
• Whether the parties entered a consent judgment concerning infringement or validity.

The absence of disclosed terms prevents a reliable calculation of the exact launch concession obtained by Apotex. It also prevents classification of the settlement under a specific reverse-payment or no-authorized-generic framework.

Did Apotex launch generic Cialis before the ’124 patent expired?

The case itself did not create a publicly documented unrestricted launch right for Apotex before the ’124 patent’s listed expiration. The broader tadalafil market nevertheless became subject to generic competition as earlier Cialis protections expired and multiple generic manufacturers entered through settlements, licenses, or label strategies.

The likely commercial distinction was between:

• Tadalafil for erectile dysfunction, where earlier patent protection had diminished or expired; and
• Tadalafil for BPH, where the ’124 patent continued to create a method-of-use barrier.

A generic erectile-dysfunction product could enter with a label that omitted BPH. That approach reduced direct patent exposure but did not eliminate all litigation risk. Prescribing patterns, pharmacy substitution, product labeling, and promotional conduct could affect an induced-infringement analysis.

What generic entry risks existed for Cialis?

Generic entry risk was high for the erectile-dysfunction market and more limited for the BPH indication.

Erectile dysfunction

The core Cialis market faced substantial generic pressure because the earliest composition and product patents had expired or were approaching expiration. Tadalafil tablets were comparatively straightforward to manufacture, and multiple established generic companies had the technical capability to produce them.

Benign prostatic hyperplasia

BPH presented a narrower entry path. Generic applicants could:

• Challenge the ’124 patent through Paragraph IV litigation.
• Exclude BPH from the proposed label.
• Seek approval for erectile dysfunction only.
• Enter under a settlement or license.
• Wait for patent expiration.

A skinny-label strategy could support regulatory approval but would not guarantee freedom from infringement claims. Lilly could argue that the generic’s label, prescribing information, or distribution practices encouraged use for BPH.

How did this case compare with other Cialis patent disputes?

The Apotex case formed part of a broader wave of Cialis-related ANDA litigation. Lilly brought similar actions against other generic manufacturers after Paragraph IV challenges to tadalafil patents.

Issue	Lilly v. Apotex	Broader Cialis litigation
Product	Tadalafil tablets	Tadalafil tablets
Principal concern	BPH method-of-use protection	Core product, formulation, and method-of-use protection
Statutory pathway	Paragraph IV ANDA litigation	Paragraph IV ANDA litigation
Key patent	U.S. 8,791,124	Multiple Cialis-listed patents
Main generic strategy	Invalidity, noninfringement, and label carve-out	Same, with different patent combinations
Public merits precedent	None reported from this case	Depended on the individual defendant and patent
Commercial outcome	Resolution without disclosed terms	Mixture of settlements, licenses, and generic entry

The most important competitive fact was that Cialis did not have a single, indivisible patent barrier. The estate consisted of patents with different claim scope and expiration dates. A generic could penetrate one indication while remaining exposed in another.

What manufacturing and intellectual-property barriers affected tadalafil entry?

Tadalafil manufacturing did not present the same barrier as a complex biologic or sterile injectable product. The product is an oral small-molecule tablet, which reduces manufacturing complexity relative to biologics, long-acting injectables, and device-integrated products.

The principal barriers were legal and regulatory:

• Pharmaceutical equivalence and bioequivalence.
• Stability and dissolution requirements.
• Control of polymorphic or solid-state characteristics, where applicable.
• Orange Book patent certifications.
• Labeling restrictions for patented indications.
• ANDA litigation costs and launch-at-risk exposure.
• Manufacturing scale and supply reliability.

The ’124 patent did not block manufacture of tadalafil as a molecule. Its significance was tied to the use of tadalafil for BPH.

What was the revenue exposure for Lilly?

Cialis was a major Lilly product during the period of the litigation. Lilly reported Cialis revenue of approximately $2.3 billion in 2017, with sales exposed to patent expiry and generic competition. [4]

The revenue risk was not binary. It varied by:

• U.S. versus international sales.
• Erectile-dysfunction versus BPH demand.
• Timing of generic entry.
• Number of generic competitors.
• Price erosion after launch.
• Whether generic products carried a BPH indication.
• Lilly’s ability to supply an authorized generic or retain branded prescribing.

A generic launch limited to erectile dysfunction could still materially reduce Cialis revenue because erectile dysfunction represented the larger commercial market. Continued protection for BPH could preserve a narrower revenue segment but would not protect the full Cialis franchise.

What is the current legal significance of the case?

Eli Lilly v. Apotex is primarily a case study in indication-specific Hatch-Waxman protection. It shows how a later method-of-use patent can delay or constrain generic approval after earlier patents protecting the active ingredient have expired.

The case did not produce a published decision resolving:

• The validity of the ’124 patent.
• The correct construction of the asserted claims.
• The scope of induced infringement based on a generic label.
• The enforceability of Lilly’s BPH patent.
• The legality of any settlement terms.

Its business significance lies in the interaction between Orange Book listing, Paragraph IV litigation, skinny-label strategy, and settlement-driven launch timing.

Key Takeaways

• Lilly sued Apotex in Delaware in January 2017 over an ANDA for generic tadalafil tablets.
• The principal patent was U.S. Patent No. 8,791,124, covering tadalafil treatment for BPH.
• The case was a Paragraph IV Hatch-Waxman action.
• The patent was a method-of-use patent, not a broad patent over tadalafil itself.
• Generic entry for erectile dysfunction was more achievable than entry with an unrestricted BPH label.
• The case ended without a reported merits judgment.
• Public materials do not disclose the settlement’s launch date or commercial terms.
• Cialis faced substantial revenue exposure from generic tadalafil competition.
• The litigation illustrates how indication carve-outs can narrow, but not eliminate, infringement risk.

FAQs About Eli Lilly v. Apotex, 1:17-cv-00015

Was Eli Lilly v. Apotex a patent infringement case?

Yes. Lilly brought the action under the Hatch-Waxman Act after Apotex submitted an ANDA with a Paragraph IV certification concerning a Cialis-listed tadalafil patent.

Which Cialis indication was protected by the asserted patent?

The asserted patent focused on tadalafil treatment for benign prostatic hyperplasia, or BPH.

Could Apotex have launched tadalafil for erectile dysfunction?

A generic applicant could pursue a label excluding the patented BPH indication, subject to FDA approval and the risk that Lilly would allege induced infringement based on the label or related conduct.

Did the court invalidate U.S. Patent No. 8,791,124?

No reported decision in this action establishes that the court invalidated the patent. The case ended without a publicly reported merits ruling.

Does this case establish when generic tadalafil entered the market?

No. The Apotex docket does not publicly establish a general tadalafil launch date or disclose the precise commercial terms governing Apotex’s entry.

References

1. U.S. District Court for the District of Delaware. (2017). Eli Lilly and Company v. Apotex, Inc., No. 1:17-cv-00015-RGA. PACER/Court docket record.

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

3. 21 U.S.C. § 355(j); 35 U.S.C. § 271(e).

4. Eli Lilly and Company. (2018). 2017 annual report. Eli Lilly and Company.